KRAS and pancreatic ductal adenocarcinoma: <h4>Introduction</h4>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy driven by KRAS mutations in ~90% of cases, with high heterogeneity and limited efficacy of single targeted agents.